Amgen Inc. (AMGN)
NASDAQ: AMGN · IEX Real-Time Price · USD
334.85
+0.55 (0.16%)
At close: Jul 26, 2024, 4:00 PM
334.90
+0.05 (0.01%)
After-hours: Jul 26, 2024, 7:08 PM EDT
Amgen Employees
Amgen had 26,700 employees as of December 31, 2023. The number of employees increased by 1,500 or 5.95% compared to the previous year.
Employees
26,700
Change (1Y)
1,500
Growth (1Y)
5.95%
Revenue / Employee
$1,106,067
Profits / Employee
$140,936
Market Cap
179.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 26,700 | 1,500 | 5.95% |
Dec 31, 2022 | 25,200 | 1,000 | 4.13% |
Dec 31, 2021 | 24,200 | -100 | -0.41% |
Dec 31, 2020 | 24,300 | 900 | 3.85% |
Dec 31, 2019 | 23,400 | 1,900 | 8.84% |
Dec 31, 2018 | 21,500 | 700 | 3.37% |
Dec 31, 2017 | 20,800 | 1,600 | 8.33% |
Dec 31, 2016 | 19,200 | 1,300 | 7.26% |
Dec 31, 2015 | 17,900 | 0 | - |
Dec 31, 2014 | 17,900 | -2,100 | -10.50% |
Dec 31, 2013 | 20,000 | 2,000 | 11.11% |
Dec 31, 2012 | 18,000 | 200 | 1.12% |
Dec 31, 2011 | 17,800 | 400 | 2.30% |
Dec 31, 2010 | 17,400 | 200 | 1.16% |
Dec 31, 2009 | 17,200 | 300 | 1.78% |
Dec 31, 2008 | 16,900 | -600 | -3.43% |
Dec 31, 2007 | 17,500 | -2,600 | -12.94% |
Dec 31, 2006 | 20,100 | 3,600 | 21.82% |
Dec 31, 2005 | 16,500 | 2,100 | 14.58% |
Dec 31, 2004 | 14,400 | 1,500 | 11.63% |
Dec 31, 2003 | 12,900 | 2,800 | 27.72% |
Dec 31, 2002 | 10,100 | 2,400 | 31.17% |
Dec 31, 2001 | 7,700 | 400 | 5.48% |
Dec 31, 2000 | 7,300 | 900 | 14.06% |
Dec 31, 1999 | 6,400 | 900 | 16.36% |
Dec 31, 1998 | 5,500 | 192 | 3.62% |
Dec 31, 1997 | 5,308 | 662 | 14.25% |
Dec 31, 1996 | 4,646 | 600 | 14.83% |
Dec 31, 1995 | 4,046 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Pfizer | 88,000 |
Sanofi | 86,088 |
Novartis AG | 76,057 |
Danaher | 63,000 |
Stryker | 26,700 |
AMGN News
- 17 days ago - ‘Crash proof' your portfolio with these 10 stocks and 3 ETFs - Market Watch
- 5 weeks ago - M&A Is Back. 4 Stocks That Could Be Targets. - Barrons
- 6 weeks ago - FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE - PRNewsWire
- 6 weeks ago - AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024 - PRNewsWire
- 7 weeks ago - AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - PRNewsWire
- 7 weeks ago - Amgen's drug meets main goal in late-stage study for rare disease - Reuters
- 7 weeks ago - AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD) - PRNewsWire
- 7 weeks ago - AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE - PRNewsWire